October 4, 2016 / 8:01 AM / 10 months ago

BRIEF-Pharma Mar and Boryung Pharm sign licensing deal for Aplidin in South Korea

1 Min Read

Oct 4 (Reuters) - Pharma Mar SA :

* Pharma Mar and Boryung Pharm have signed a licensing agreement to commercialize the marine-derived anticancer drug Aplidin (plitidepsin) in South Korea

* Under terms of the deal, Pharma Mar will receive an upfront payment, royalties and additional remunerations upon achieving regulatory milestones with Aplidin

* PharmaMar will retain exclusive production rights and will supply the finished product to Boryung Pharm for commercial use Source text: bit.ly/2dNiRP8

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below